These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32407947)

  • 41. Effectiveness of fluticasone furoate 110 microg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen.
    Jacobs R; Martin B; Hampel F; Toler W; Ellsworth A; Philpot E
    Curr Med Res Opin; 2009 Jun; 25(6):1393-401. PubMed ID: 19419338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term immunological effects of Japanese cedar pollen-based subcutaneous immunotherapy.
    Inuo C; Ando H; Tanaka K; Nakajima Y; Tsuge I; Urisu A; Kondo Y
    Allergol Int; 2018 Jul; 67(3):408-410. PubMed ID: 29198713
    [No Abstract]   [Full Text] [Related]  

  • 43. Long-term sublingual immunotherapy provides better effects for patients with Japanese cedar pollinosis.
    Hamada S; Kobayashi Y; Sakamoto D; Shimamura A; Kuroda K; Kawachi R; Kanda A; Asako M; Gotoh M; Okubo K; Tomoda K; Iwai H
    Auris Nasus Larynx; 2021 Aug; 48(4):646-652. PubMed ID: 33526319
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.
    Mäkelä MJ; Gyllfors P; Valovirta E; Steffensen MA; Grønager PM; Savolainen J; Winther L
    Clin Ther; 2018 Apr; 40(4):574-586.e4. PubMed ID: 29551533
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis.
    Patterson AM; Bonny AE; Shiels WE; Erwin EA
    Ann Allergy Asthma Immunol; 2016 Feb; 116(2):168-70. PubMed ID: 26706294
    [No Abstract]   [Full Text] [Related]  

  • 46. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
    Winther L; Malling HJ; Mosbech H
    Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant Fusion Allergens, Cry j 1 and Cry j 2 from Japanese Cedar Pollen, Conjugated with Polyethylene Glycol Potentiate the Attenuation of Cry j 1-Specific IgE Production in Cry j 1-Sensitized Mice and Japanese Cedar Pollen Allergen-Sensitized Monkeys.
    Fujimura T; Fujinami K; Ishikawa R; Tateno M; Tahara Y; Okumura Y; Ohta H; Miyazaki H; Taniguchi M
    Int Arch Allergy Immunol; 2015; 168(1):32-43. PubMed ID: 26524293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial.
    Park HJ; Kim SH; Shin YS; Park CH; Cho ES; Choi SJ; Park SH; Jung JH; Kang IG; Lee MS; Kim DW; Lee SM; Yang MS; Lee SP
    Respir Res; 2021 Jun; 22(1):170. PubMed ID: 34088322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a randomized controlled trial.
    Murakami D; Sawatsubashi M; Omori H; Saito A; Kato A; Komune S; Nakagawa T
    Sci Rep; 2017 Apr; 7():46142. PubMed ID: 28397833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
    Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE
    J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
    Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
    Allergy; 2009 Sep; 64(9):1394-401. PubMed ID: 19764942
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
    Panzner P; Petrás M; Sýkora T; Lesná I
    Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy.
    Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M
    Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cry j 1-induced synthesis of interleukin-5 and interferon-gamma by peripheral blood mononuclear cells of patients with seasonal allergic rhinitis due to Japanese cedar pollens.
    Nakai Y; Ohashi Y; Tanaka A; Kakinoki Y; Washio Y; Masamoto T; Yamada K; Nakai Y; Ohmoto Y
    Acta Otolaryngol Suppl; 1998; 538():143-51. PubMed ID: 9879414
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Biedermann T; Kuna P; Panzner P; Valovirta E; Andersson M; de Blay F; Thrane D; Jacobsen SH; Stage BS; Winther L
    J Allergy Clin Immunol; 2019 Mar; 143(3):1058-1066.e6. PubMed ID: 30654054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
    Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
    J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis.
    Zenner HP; Baumgarten C; Rasp G; Fuchs T; Kunkel G; Hauswald B; Ring J; Effendy I; Behrendt W; Frosch PJ; Przybilla B; Brunner FX; Merk HF; Kapp A; Schnitker J; Wolf H
    J Allergy Clin Immunol; 1997 Jul; 100(1):23-9. PubMed ID: 9257783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study.
    Wahn U; Klimek L; Ploszczuk A; Adelt T; Sandner B; Trebas-Pietras E; Eberle P; Bufe A;
    J Allergy Clin Immunol; 2012 Oct; 130(4):886-93.e5. PubMed ID: 22939758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
    Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
    J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.